ReviewAmerican journal of respiratory and critical care medicine2005
Pathogen-host interactions in Pseudomonas aeruginosa pneumonia.
Review in American journal of respiratory and critical care medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02315547 (Guangzhou Institute of Respiratory Disease), which is not on this map. Cited by 399 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Guangzhou Institute of Respiratory Disease
Who cites it
399 citing papers in PubMed, 2 syntheses or guidelines pooled it, 793 citations in OpenAlex.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Outbreak investigations after identifying carbapenem-resistant Pseudomonas aeruginosa: a systematic review.Antimicrobial resistance and infection control · 2023Pooled it
- Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease.Nature immunology · 2022Trial
- Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.Critical care (London, England) · 2020Trial
- Article
- TheVirulence · 2026Article
- Is less always more? Ceftazidime/avibactam alone or in combination to treat infections caused by Pseudomonas aeruginosa: a retrospective observational multi-centre cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Synthesis, characterization, shelf life and optimization of process parameter of plasma-activated hydrogel production for Staphylococcus aureus Inhibition.Scientific reports · 2026Article
- Microbiological Analysis Following Periodontal Treatment in Individuals with Bronchiectasis.Microorganisms · 2026Article
- Monosodium Glutamate InhibitsMicroorganisms · 2026Article
- Direct interaction between phosphotransferase LpxT and ArnT modulates polymyxin B resistance inMicrobiology spectrum · 2026Article
- A novel approach to combatMicrobiology spectrum · 2026Article
- Exploring Persistent Apical Periodontitis in Humans: Integrative Genetic, Histological and Microbiological Perspectives for Translational Research.International endodontic journal · 2026Article
- Article
- Biological characterization of multidrug-resistantMicrobiology spectrum · 2026Article
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Safety Assessment ofJournal of toxicology · 2026Article
- Modulation of macrophage survival duringFrontiers in cellular and infection microbiology · 2026Review
- Evaluating serum TNF α in relation to bronchiectasis severity: Insights from FACED and BSI scoring systems.Lung India : official organ of Indian Chest Society · 2026Article
- Plasmid replication initiator protein TrfA represses the host type III secretion system inmBio · 2025Article
339 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Pseudomonas aeruginosa is an important pathogen causing a wide range of acute and chronic infections. P. aeruginosa rarely causes infection in the normal host, but is an efficient opportunistic pathogen causing serious infections in patients who are mechanically ventilated, individuals who are immunocompromised, and patients with malignancies or HIV infection. Among these risk groups, the most vulnerable hosts are neutropenic and patients who are mechanically ventilated. In addition, P. aeruginosa is the most prevalent chronic infection contributing to the pathogenesis of cystic fibrosis. Because of the ubiquitous nature of P. aeruginosa and its ability to develop resistance to antibiotics, it continues to be problematic from a treatment perspective. The pathogenicity of P. aeruginosa is largely caused by multiple bacterial virulence factors and genetic flexibility enabling it to survive in varied environments. Lung injury associated with P. aeruginosa infection results from both the direct destructive effects of the organism on the lung parenchyma and exuberant host immune responses. This article focuses on the major bacterial virulence factors and important aspects of the host immunity that are involved in the pathogenesis of serious P. aeruginosa infection. In addition to antibiotic therapy, strategies directed toward enhancing host defense and/or limiting excessive inflammation could be important to improve outcome in P. aeruginosa lung infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.